It was hush-hush as the FDA barely announced its decision to require the makers of attention deficit drugs (like Adderall) to add labels on their drugs announcing heart problems and psychiatric warnings. This lack of enthusiasm was questioned by politicians as to the FDA’s loyalty toward pharmaceutical giants or the public safety.
Months after two FDA advisory panels offered conflicting opinions over the warnings, in May 2006 the FDA asked most ADHD drug makers to add warnings. Its decision was made public when the FDA released a letter GlaxoSmithKline, maker of Dexedrine, sent to doctors. Others include Adderall, Focalin, and Concerta.
Some analysts and doctors say the warnings are unlikely to affect the millions of ADHD prescriptions written each month. (Chron.com)